These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 11812075)

  • 21. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. boccardo@hp380.ist.unige.it.
    Boccardo F; Rubagotti A; Amoroso D; Mesiti M; Romeo D; Sismondi P; Giai M; Genta F; Pacini P; Distante V; Bolognesi A; Aldrighetti D; Farris A
    J Clin Oncol; 2000 Jul; 18(14):2718-27. PubMed ID: 10894871
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hormonal approaches to breast cancer treatment and prevention: an overview.
    Vogel CL
    Semin Oncol; 1996 Aug; 23(4 Suppl 9):2-9. PubMed ID: 8824459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant endocrine therapy for premenopausal women: Type and duration.
    Francis PA
    Breast; 2017 Aug; 34 Suppl 1():S108-S111. PubMed ID: 28669713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
    Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
    Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of tamoxifen with postsurgical irradiation may improve survival in estrogen and progesterone receptor-positive male breast cancer.
    Fogh S; Hirsch AE; Langmead JP; Goldberg SI; Rosenberg CL; Taghian AG; Powell SN; Kachnic LA
    Clin Breast Cancer; 2011 Mar; 11(1):39-45. PubMed ID: 21421521
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report.
    Markman M; Iseminger KA; Hatch KD; Creasman WT; Barnes W; Dubeshter B
    Gynecol Oncol; 1996 Jul; 62(1):4-6. PubMed ID: 8690289
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Factors predicting failure of adjuvant hormonotherapy of breast carcinoma. A study in tamoxifen treated patients].
    Petráková K; Nenutil R; Grell P; Fabian P; Zichová I; Svoboda M; Palácová M; Vyzula R
    Klin Onkol; 2008; 21(5):303-8. PubMed ID: 19202962
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
    Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
    Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
    Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
    Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What is the role of ovarian ablation in the management of primary and metastatic breast cancer today?
    Prowell TM; Davidson NE
    Oncologist; 2004; 9(5):507-17. PubMed ID: 15477635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients.
    Stendahl M; Rydén L; Nordenskjöld B; Jönsson PE; Landberg G; Jirström K
    Clin Cancer Res; 2006 Aug; 12(15):4614-8. PubMed ID: 16899609
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estrogen and progesterone receptors in benign ovarian tumors of menopausal breast cancer patients treated with tamoxifen.
    Cohen I; Bernheim J; Fishman A; Shapira J; Tepper R; Beyth Y; Cordoba M; Yigael D; Altaras MM
    Gynecol Obstet Invest; 1998 Aug; 46(2):116-22. PubMed ID: 9701692
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ovarian ablation for premenopausal breast cancer: A review of treatment considerations and the impact of premature menopause.
    Nourmoussavi M; Pansegrau G; Popesku J; Hammond GL; Kwon JS; Carey MS
    Cancer Treat Rev; 2017 Apr; 55():26-35. PubMed ID: 28288389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer.
    Dignam JJ; Dukic V; Anderson SJ; Mamounas EP; Wickerham DL; Wolmark N
    Breast Cancer Res Treat; 2009 Aug; 116(3):595-602. PubMed ID: 18830816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
    Mouridsen HT; Robert NJ
    Eur J Cancer; 2005 Aug; 41(12):1678-89. PubMed ID: 16098456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term risk of breast cancer recurrence: the need for extended adjuvant therapy.
    Kaufmann M; Rody A
    J Cancer Res Clin Oncol; 2005 Aug; 131(8):487-94. PubMed ID: 15915367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The predictive value of HER2 in breast cancer.
    Piccart M; Lohrisch C; Di Leo A; Larsimont D
    Oncology; 2001; 61 Suppl 2():73-82. PubMed ID: 11694791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.
    Bernhard J; Luo W; Ribi K; Colleoni M; Burstein HJ; Tondini C; Pinotti G; Spazzapan S; Ruhstaller T; Puglisi F; Pavesi L; Parmar V; Regan MM; Pagani O; Fleming GF; Francis PA; Price KN; Coates AS; Gelber RD; Goldhirsch A; Walley BA
    Lancet Oncol; 2015 Jul; 16(7):848-58. PubMed ID: 26092816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
    Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
    Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.